Veraxa Biotech partners with Ardigen on AI-enabled drug discovery for BiTAC pipeline

• Veraxa Biotech entered a collaboration with Ardigen to apply AI tools to its BiTAC pipeline in oncology.
• Work targets improved selection of dual cancer targets for conditionally active T cell engagers, with potential expansion to antibody-drug conjugates.
• Strategy aims to reduce on-target, off-tumor toxicity by using an “AND-gate” approach that activates only when two targets co-express on cancer cells.
• Initial focus includes AI models to integrate industry preclinical and clinical datasets to identify synergistic target pairs and refine program design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130700OMX_____CNEWS_EN_GNW1001212497_en) on July 13, 2026, and is solely responsible for the information contained therein.